Durvalumab After chemoRadioTherapy for NSCLC patients

Førde D, Kilvær T, Pedersen MI, Lombardi AP, D'arsiè I, Paulsen EE, Busund LR, Rakaee M, Dønnem T, Andersen S (2025)
Prognostic impact of miR-17-5p and miR-20a-5p in NSCLC diverge in subgroups according to lymph node status
Front Oncol, 15, 1606933
DOI 10.3389/fonc.2025.1606933, PubMed 41079079

Scheiner B, Lombardi P, D'Alessio A, Kim G, Tafavvoghi M, Petrenko O, Goldin RD, Fulgenzi CAM, Torkpour A, Balcar L, Mauri FA, Pomej K, Himmelsbach V, Barsch M, Celsa C, Cabibbo G, Cheon J, Krall A, Hucke F, Di Tommaso L, Bernasconi M, Rimassa L, Samson A, Stefanini B, Mozayani B et al. (2025)
Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
J Immunother Cancer, 13 (10)
DOI 10.1136/jitc-2024-010975, PubMed 41052886

Nassar AH, Kim C, Adeyelu T, Bou Farhat E, Abushukair H, Rakaee M, Matteson K, Lau SF, Takabe Y, Ocejo A, Ardeshir-Larijani F, Leal T, Ramalingam S, Alam S, Gray JE, Hicks J, Kaldas D, Baena J, Berjaga MZ, Nana FA, Grohe C, Leuders H, Citarella F, Cortellini A, Mingo EC et al. (2025)
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma
Nat Commun, 16 (1), 7717
DOI 10.1038/s41467-025-63091-0, PubMed 40830141